sarizotan sarizotan sarizotan (emd-128,130) is a selective 5-ht1a receptor agonist and d2 receptor antagonist, which has antipsychotic effects, and has also shown efficacy in reducing dyskinesias resulting from long-term anti-parkinsonian treatment with levodopa. sarizotanclinical datapregnancycategory n/a routes ofadministrationoralatc codenonelegal statuslegal status discontinued identifiers iupac name 1--n-(methyl)methanamine cas number351862-32-3pubchem cid6918388chemspider2319847unii467lu0ucuwcomptox dashboard (epa)dtxsid80956632 chemical and physical dataformulac22h21fn2omolar mass348.421 g·mol−13d model (jsmol)interactive image smiles c1cc2=cc=cc=c2o1cncc3=cn=cc(=c3)c4=cc=c(c=c4)f in june 2006, the developer merck kgaa announced that the development of sarizotan was discontinued, after two sarizotan phase iii studies (paddy i, paddy ii) failed to meet the primary efficacy endpoint and neither the phase ii findings nor the results from preclinical studies could be confirmed. no statistically significant difference of the primary target variable between sarizotan and placebo could be demonstrated.